

## ONCOLOGY MEDICINES

### MARKETED PRODUCTS

**Arimidex** (anastrozole) is the world's leading aromatase inhibitor for the treatment of breast cancer.

**Casodex** (bicalutamide) is the world's leading anti-androgen therapy for the treatment of prostate cancer.

**Zoladex** (goserelin acetate implant), in one- and three-month depots, is the world's second largest LHRH agonist for the treatment of prostate cancer, breast cancer and certain benign gynaecological disorders.

**Iressa** (gefitinib) is an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that acts to block signals for cancer cell growth and survival in non-small cell lung cancer.

**Faslodex** (fulvestrant) is an injectable oestrogen receptor antagonist for the treatment of breast cancer, with no known agonist effects, that down-regulates the oestrogen receptor.

**Nolvadex** (tamoxifen citrate) remains a widely prescribed breast cancer treatment outside the US.

**Ethylol** (amifostine) is used to help prevent certain side effects of specific types of chemotherapy and radiotherapy that are used to treat cancer.

**Abraxane**<sup>®</sup> (paclitaxel protein-bound particles for injectable suspension) (albumin-bound), discovered, developed and owned by Abraxis BioScience, Inc., uses a novel technology to deliver paclitaxel for the treatment of breast cancer. We co-promote Abraxane<sup>®</sup> in the US under an agreement with Abraxis.

### 2007 IN BRIEF

- > **Arimidex sales up 10% to \$1.7 billion.** It remains the leading hormonal breast cancer therapy in the US, Japan and France.
- > **Casodex sales growth continued with total sales of over \$1 billion, up 6%.**
- > **Zoladex sales of over \$1 billion, up 4%.**
- > **ZD4054 progressed into phase III development for hormone-resistant prostate cancer.**
- > **Phase III trials of Zactima in non-small cell lung cancer (NSCLC) and in medullary thyroid cancer continued.**
- > **Pivotal trials of Recentin in colorectal cancer (CLC) and NSCLC continued to recruit patients.**

### PERFORMANCE

	2007			2006			2005	2007 compared to 2006		2006 compared to 2005	
	Sales \$m	Growth underlying \$m	exchange effects \$m	Sales \$m	Growth underlying \$m	exchange effects \$m		Growth underlying %	Growth reported %	Growth underlying %	Growth reported %
Arimidex	1,730	151	71	1,508	338	(11)	1,181	10	15	29	28
Casodex	1,335	74	55	1,206	104	(21)	1,123	6	11	9	7
Zoladex	1,104	39	57	1,008	17	(13)	1,004	4	10	1	-
Iressa	238	(1)	2	237	(30)	(6)	273	-	-	(11)	(13)
Faslodex	214	18	10	186	45	1	140	10	15	32	33
Nolvadex	83	(8)	2	89	(22)	(3)	114	(9)	(7)	(19)	(22)
Abraxane <sup>®</sup>	62	44	-	18	18	-	-	244	244	-	-
Ethylol <sup>1</sup>	43	43	-	-	-	-	-	n/m	n/m	n/m	n/m
Other	10	(1)	1	10	-	-	10	(10)	-	-	-
<b>Total</b>	<b>4,819</b>	<b>359</b>	<b>198</b>	<b>4,262</b>	<b>470</b>	<b>(53)</b>	<b>3,845</b>	<b>8</b>	<b>13</b>	<b>12</b>	<b>11</b>

<sup>1</sup> Sales of this MedImmune product are consolidated in AstraZeneca accounts from 1 June 2007. As a result, there are no prior period sales included.

### PIPELINE

Compound	Mechanism	Areas under investigation	Phase			Estimated filing date	
			I	II	III	Europe	US
<b>NCEs</b>							
Zactima	VEGF/EGF TK inhibitor with RET kinase activity	NSCLC	■	■	■	4Q 2008	4Q 2008
Recentin <sup>2</sup>	VEGF signalling inhibitor (VEGFR-TKI)	NSCLC and CRC	■	■	■	2010	2010
Recentin	VEGF signalling inhibitor (VEGFR-TKI)	recurrent glioblastoma	■	■	■	2010	2010
ZD4054	endothelin A receptor antagonist	hormone-resistant prostate cancer	■	■	■	2011	2011
Zactima	VEGF/EGF TK inhibitor with RET kinase activity	medullary thyroid cancer	■	■		4Q 2008	4Q 2008
AZD6244 (ARRY-142886)	MEK inhibitor	solid tumours	■	■			
AZD2281	PARP inhibitor	breast cancer	■	■			
AZD0530	SRC kinase inhibitor	solid tumours and haematological malignancies	■	■			
MEDI-561	Hsp 90 inhibitor	solid tumours	■	■			2010
AZD1152	aurora kinase inhibitor	solid tumours and haematological malignancies	■				
AZD4769	EGFR tyrosine kinase inhibitor	solid tumours	■				
AZD4877	cell cycle agent	solid tumours and haematological malignancies	■				
AZD8931	erbB kinase inhibitor	solid tumours	■				
AZD7762	CHK1 kinase inhibitor	solid tumours	■				
AZD8330 (ARRY-424704)	MEK inhibitor	solid tumours	■				
CAT-8015	recombinant immunotoxin	haematological malignancies	■				
MEDI-538	CD19 B cells	leukaemia/lymphoma	■				
<b>Line extensions</b>							
Faslodex	oestrogen receptor antagonist	first-line advanced breast cancer	■	■	■		
Faslodex	oestrogen receptor antagonist	adjuvant	■	■	■		
Iressa	EGFR-TK inhibitor	NSCLC	■	■	■	2Q 2008	

<sup>2</sup> This compound is in phase II/III development. For discontinued projects see page 30.